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Differentiation of smooth muscle phenotypes in mouse mesangial cells.
Smooth muscle a-actin (SMA) mRNA, a marker of vascular smooth
muscle cells, was identified in the normal glomerular mesangium both in
vivo and in vitro. Several populations of mesangial cells were studied to
determine if SMA and basement membrane collagen were regulated
together. The levels of SMA expression, which could be linked to the stage
of differentiation, were different for the differing cell populations. One cell
population had high SMA and type IV collagen levels at its early passages.
The others expressed both interstitial and basement membrane collagens.
The first population developed these phenotypic features at later passages.
The levels of SMA and al(IV) collagen expression were regulated
together in concert, whereas the cs2(I) collagen levels were expressed
inversely to SMA and al(IV) collagen. Both SMA and type IV collagen
were controlled by the methylation states of the cis-regulators; however,
type I collagen was mainly regulated by the trans-acting regulators.
Treatment with 5-azacytidine converted the cells of a fibroblast-phenotype
to a smooth muscle cell-like phenotype. These cell lines may be useful for
studying the differentiation process in vitro.
Glomerular mesangial cells are derived from the primitive
metanephric mesenchyme, and invade the primitive glomerular
epithelium to form the smooth muscle component of the glomer-
ular vasculature. The mesangial extracellular matrix (ECM) in the
fully formed glomerulus contains only basement membrane com-
ponents [11. Recently, immunohistologic techniques have failed to
demonstrate smooth muscle a-actin (SMA) in mature mesangial
cells in vivo. However, mesangial cells in vitro expressed SMA [2].
It is therefore critical to clarify whether the mesangial cells in
vivo represented a smooth muscle cell phenotype. We studied the
phenotypic state of mesangial cells in vivo, derived from normal
kidney, by in situ hybridization with a specific probe for SMA and
by a modified, sensitive immunoperoxidase technique. The ex-
pression of SMA mRNA and protein was found only in the
majority of mesangial cells and in smooth muscle cells from the
blood vessels in the adult mouse kidney. The expression changed
dramatically during differentiation from newborn mice to one-
week-old mice.
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On the other hand, mesangial cells in vitro have also been found
to principally synthesize interstitial matrix components [3, 4]. This
may have some relevance to certain disease states in both animals
and humans in which type I collagen and SMA have been found
in the sclerotic matrix [5—7]. This phenotypic modulation of
mesangial cells is also important in the development of glomeru-
lar injury. We examined mesangial cells in vitro to address the
following questions: (a) were they representative of their in vivo
counterparts; (b) were they derived from a small and non-
representative population of mesangial cells; or (c) did their
phenotype change in vitro? We addressed these questions by
determining whether mesangial cells in vivo and in vitro fulfilled
the criteria for being members of the smooth muscle cell family.
SMA, a specific marker of vascular smooth muscle cells, was
expressed at both the mRNA and peptide levels in vivo and in vitro
[8].
We established four different populations of mesangial cells in
vitro, which were isolated independently from normal or experi-
mental mice. These cell lines represented the different differen-
tiation states of smooth muscle cells, which was measured by SMA
expression in association with the magnitude of basement mem-
brane component (type IV collagen) expression.
These phenotypic changes were regulated by transcriptional
modulation, which was determined by modification to the cis-
elements and the activity of trans-elements of each gene. We
found that different genes were controlled by different regulatory
mechanisms. These studies suggest that these mesangial cell lines
may be useful as tools for exploring the stage of differentiation in
mesangial cells, which is of critical importance for in vitro exper-
iments.
Methods
Cell culture
Glomerular mesangial cell lines were established from normal
four-week-old mice (C57BL/6JxSJL/J), and from nonobese dia-
betic mice (Table 1). Isolated patches of cells containing no more
than 50 cells were segregated by a cloning ring from diluted plated
primary cultures, and further subcultured to develop each cell
line. The cells, which were identified as previously described [3],
appeared to be phenotypically stable for at least 25 passages. The
cells were plated onto 100 mm plastic dishes (Nunc) coated with
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Table 1. Mesangial cell lines
Cell Line Passages Source of the cells Doubling time (hours)
30E <25 C57BLISJL 25.1 0.14
30L >45 C57BL/SJL 18.6 0.55
SlO <25 C57BL/SJL 17.9 0.05
Ni <25 NOD mice 17.4 0.40
N2 <25 NOD mice 19.0 1.00
0.3 j.tg/cm2 fibronectin (Collaborative Research), and were main-
tained in B medium (a 3:1 mixture of MEM/F12 modified with
trace elements) supplemented with 6 m glucose, 1 mM glu-
tamine, 100 U/mI penicillin, 100 ig/ml streptomycin, and 20%
fetal serum albumin (FBS) (Gibco). The cells were passaged
weekly using a trypsin-EDTA (Gibco)
Cell growth
Twenty thousand cells were plated onto 24-well plates coated
with 0.3 .tg/cm2 fibronectin, in B medium containing 20% FBS.
The cells were incubated for one day, the cell layer was rinsed with
medium, and the medium was replaced with B medium containing
2% FBS. The cell numbers were determined with a particle cell
counter on days 0, 1, 2 and 3.
RNA isolation and Northern blot analysis
A total of 1.2 X 106 mesangial cells in B medium supplemented
with 20% FBS were plated onto 100 mm dishes coated with
fibronectin (0.3 .tg/cm2). After four days, the cells were washed
with PBS, and the total RNA was extracted using the guanidine
isothiocyanate method [9]. Five micrograms of RNA were run on
a 1% agarose-formalin gel, and then transferred to a Nytran
membrane (Schleicher & Schuell). The filters were hybridized
with a 32P labeled probe specific for SMA (the 160 bp DdeI-EcoRI
fragment of pSA481) [10].
RNA probe preparation
The cDNA (p1234) in pGEM2 (Promega) and pGM1O1 in
pGEM7Zf(—) (Promega) code for mouse csl(IV) collagen and
mouse a2(I) collagen, respectively [6, 11, 12]. The 70 bp of the
EcoRI and Hindlil fragment of pSA481 was subcloned into
pGEM7Zf(—) (pSA481HE) [101, and the 250 bp of the EcoRI
and HindIII fragment of the mouse GAPDH eDNA was sub-
cloned into pGEM7Zf(—) (pMGAP1) [13]. The orientation of the
insert was analyzed by determining the size of the digestible
fragments with restriction enzymes. Radiolabeled probes were
prepared by linearizing the constructs withApal (pGM1O1), PvuII
(p1234), EcoRl (pMGAP1) and HindIIl (pSA481HE). Prior to
transcription, the linearized pGM1O1 was treated with Klenow
DNA polymerase (Promega) to convert the 3'-protruding ends to
blunt termini. The transcription reaction was performed accord-
ing to Melton [141, using 1 j.g of template DNA, 32P-UTP
(Amersham) and SP6 or T7 RNA polymerase (Promega). Biotin-
11-UTP (Enzo) was used for the transcription of pSA48IHE for
in situ hybridization. The control (sense probe), pSA481HE, was
digested with EcoRI and labeled with biotin-11-UTP. The 100 bp
ladder (BRL) or the Hinfl marker (Promega), which was
labeled by replacement synthesis using T4 DNA polymerase
(BRL), served as the controls for size.
In situ hybridization
The kidneys of eight-week-old mice (C57BL/6JxSJL/J) were
perfused by the retrograde aortic route with phosphate buffered
saline (PBS: 9.5 m phosphate, 137 m'vi NaC1, pH 7.3) and then
frozen in dry ice/acetone. Ten micrometer eryostat sections were
cut and placed onto slides coated with aminoalkylsilane (Sigma),
dried at room temperature (RT) and then fixed with 4% parafor-
maldehyde-PBS. The sections were washed with PBS and dehy-
drated with increasing concentrations of ethanol. They were then
treated with the following reagents in order: 0.2 N HC1 for 20
minutes, diethyl pyrocarbonate water for five minutes, 2 x SSC
for 10 minutes, 0.1 x SSC for 30 minutes, 10 g/ml of proteinase
K for 10 minutes, 2 .tg/ml of glycine in PBS for 30 seconds, 4%
paraformaldehyde in PBS for 20 minutes and finally a PBS rinse
[151. After acetylation, the sections were washed, dehydrated with
ethanol, prehybridized at 45°C and then hybridized with the
biotin-labeled probe at 45°C overnight. After washing, the sec-
tions were incubated with an avidin DH-biotin-peroxidase com-
plex (Dako). The reaction products were developed with 3,3'-
diaminobenzidine and counterstained with fast green FCF.
Immunoperoxidase technique
Cryostat sections from newborn, one week, two week, three
week, four week, five week, six week, seven week and eight-week-
old mice (C57BL/6JxSJL/J) were fixed with acetone, washed, and
blocked with 10% goat serum-PBS. They were then incubated
with biotin-labeled mouse monoclonal anti-SMA (IgG2a) (Sig-
ma), which had been prepared by incubating the IgG fraction of
the antibody with sulfo-NHS-biotin (Pierce). The sections were
washed and incubated with an avidinDH-biotin-peroxidase com-
plex (Vectastain Elite ABC kit, Vector Laboratories). The reac-
tions were visualized with a metal enhanced DAB substrate
(Pierce).
Solution hybridization RNase protection assay
The RNA probe (4 x i0 cpm) and the test RNA were
hybridized overnight at 45°C. RNase A (40 j.g/ml) was added to
each tube, and the tubes were incubated for one hour at 30°C.
RNase resistant fragments were analyzed by 3.5% or 7% poly-
acrylamide-8 M urea gel electrophoresis and autoradiography [6].
The protected bands for each RNA probe had the same size as the
coding sequence for the specific mRNA, thus providing evidence
for the specificity of this technique. The subsequent autoradio-
grams were analyzed by densitometry.
Detection of SMA by Western blot analysis
Mesangial cells were cultured in dishes coated with fibronectin
(0.3 g/cm2) in B medium supplemented with 20% FBS for 72
hours. The cells were washed with B medium, and then incubated
for an additional 24 hours in B medium containing 0.1% bovine
serum albumin. After washing with PBS, the cells were extracted
with 0.2 M Tris, pH 7.4 containing 8 M urea, 5 m EDTA, and 5
mM dithiothreitol [16]. The cells were homogenized, incubated at
room temperature for one hour, and then centrifuged. The
supernatants were collected and precipitated with 5 volumes of
ethanol and 0.5 volumes of glacial acetic acid. The supernants
were maintained at —20°C for two hours, and centrifuged again.
After washing with 80% ethanol, the precipitates were dissolved
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in the homogenizing buffer and the protein concentration deter-
mined (Bio-Rad). Twenty micrograms of protein were loaded
onto a 4 to 12% SDS polyacrylamide gel, and subjected to
electrophoresis. The proteins were then transferred onto nitrocel-
lulose filters, and the filters were washed and preincubated with
5% nonfat dry milk and 0.1% nonidet P-40 in PBS. The filters
were then incubated with biotin-labeled mouse monoclonal anti-
SMA antibodies [8] and streptavidin-alkaline phosphatase. The
reaction products were visualized with nitro blue tetrazolium and
5-bromo-4-chloro-3-indolyl-phosphate, and were subsequently
analyzed by densitometry.
Secretion of types I and IV collagen
Mesangial cells were plated onto 100 mm dishes coated with 0.3
tg!cm2 fibronectin in B medium supplemented with 20% FBS,
and cultured for three days. The cells were then rinsed with
serum-free medium, and incubated in medium containing 0.1%
bovine serum albumin, 50 tg/ml L-ascorbic acid and 80 tLg/ml
p-aminopropionitrile fumarate for 24 hours. The medium was
removed, and protease inhibitors were added to a final concen-
tration of 25 mivi EDTA, 1 mivi phenylmethylsulfonyl fluoride
(PMSF) and 10 m N-ethylmaleimide. Mouse type IV collagen,
purified from an Engelbreth-Holm-Swarm mouse sarcoma, was
isolated as previously described [17]. Rat type I collagen was
purchased from Sigma. Rabbit anti-mouse type IV collagen
(HK68) and rabbit anti-mouse type I collagenantisera have been
described previously [2, 6]. Type I and IV collagens were quanti-
tated by a competitive enzyme-linked immunoassay utilizing
immunoplates coated with 1 g/ml of type I collagen or 2 j.gIml of
type IV collagen, respectively.
DNA methylation pattern
High molecular weight cellular DNA was prepared from each
cell line according to the procedures of Britten, Graham and
Neufeld [18]. Aliquots (5 to 10 .tg) of DNA were digested with
HpaII or MspI restriction endonucleases (5 U/itg of DNA) for 18
hours at 37°C. The DNA samples were electrophoresed on a 1%
agarose gel, and transferred to a Nytran membrane for Southern
blotting [19]. The 0.85 kbpXhol fragment of the 5' end of al(IV)
collagen (p56) [20, 21] and the 0.85 kbp XhoI fragment of a2(I)
collagen (pAZ1002) [12] contained both promoter and enhancer
elements from each gene. The 1.1 kbp SalI-BamHI fragment of
the 5' end of SMA (SMP-1) contained the promoter element [22].
These fragments were then labeled by the random primer method,
and were used as probes.
DNA transfection
The cd(IV) promoter-enhancer-CAT construct (p56) and the
a2(I) promoter-enhancer-CAT construct (pR4O) have been de-
scribed previously [21, 23]. SMP-1 contains 1074 bp from proximal
5'-flanking region, plus the 43 bp 5'-untranslated region, cloned
into the SalI-BamHI site of pBLCAT3 [24]. SMP-1 contains the
promoter portion of SMA and the enhancer element of SV4O.
Four >< i0 cells (30E, Ni and N2) were plated onto a 60 mm dish
four hours prior to the transfection with the plasmid DNA using
the standard calcium phosphate coprecipitation technique [25].
Typically, 15 g of CAT reporter plasmid and 4 .tg of pSV-13-
galactosidase (Promega) (internal control for the transfection
efficiency) were used. The cells were exposed to the precipitate for
four hours, rinsed, and B medium containing 20% PBS was again
added. After 48 hours, the cells were harvested and assayed for
CAT and /3-galactosidase activity [26, 27]. CAT (Pharmacia) and
J3-galactosidase (Promega) were used as the standards. pSVOCAT
and pSV2CAT were also used for negative and positive controls,
respectively [25]. A correction factor for differences in the trans-
fection efficiency was obtained by normalizing the CAT activity to
the /3-galactosidase activity, and then subtracting the background
as determined by transfection with pSVOCAT. The final result was
expressed as a percentage of the CAT activity following transfec-
tion with pSV2CAT.
5-Azacytidine treatment
Two hundred thousand mesangial cells per well (30E and 30L)
were cultured in a six well plate for four days in the presence or
absence of iO— M 5-azacytidine [28]. The total RNA was ex-
tracted and specific mRNAs were measured by the solution
hybridization RNase protection assay. Prior to the transient DNA
transfection, 4 X 10 30L cells were cultured with or without iO
M 5-azacytidine for four days. The cells were trypsinized and
plated onto a 60 mm dish. After four hours in culture, the medium
was replaced with B medium containing 5% FBS and 100 j.g/ml
chloroquine with or without 5-azacytidine. The DNA transfection
was performed with a2(I)!CAT (pR4O) and pSV-f3-galactosidase
according to the methods described above. After four hours, the
cells were washed, treated with 15% glycerol/HEPES buffered
saline (25 mM HEPES, 140 mivi NaCl, 5 m KC1, 0.75 mM
phosphate, 6 m dextrose, pH 7.05) for 30 seconds, and then
cultured for 48 hours in B medium containing 20% FBS with or
without 5-azacytidine for the CAT and f3-galactosidase assays.
These data were also corrected as described above.
Preparation of nuclear extracts
Cells from confluent cultures were scraped into phosphate-
buffered saline, and pelleted at 1850 X g in a refrigerated
centrifuge. The cells were resuspended in a hypotonic buffer [10
mM HEPES, (pH 7.9)/1.5 mM MgC12I1O mivi KC1IO.2 msi PMSF/
0.5 mM dithiothreitol (DTT)], and allowed to swell on ice for 10
minutes. The cells were then homogenized in a glass Dounce
homogenizer using a type B pestle. The nuclei were pelleted at
3300 x g for 15 minutes in a refrigerated centrifuge. The pellet
was resuspended in a low-salt buffer [20 mi HEPES (pH 7.9)!
25% glycerolll.5 mivi MgC12I2O mM KCI!0.2 mM EDTAIO.2 mM
PMSF/0.2 m'vi DTT] and stirred gently. An equal volume of
high-salt buffer [20 mivi HEPES (pH 7.9)125% glycerol/1.5 mM
MgCl2/i.2 M KC1/0.2 mivi EDTA!0.2 mM PMSF/0.2 mrvi Dlii] was
also added. The nuclei were centrifuged for 30 minutes at 25000
x g and the nuclear extracts dialyzed against 200 ml of dialysis
buffer [20 mM HEPES (pH 7.9)120% glycerol!100 mM KC1/0.2 mM
EDTA/0.2 mivi PMSF!0.5 ms DTr] overnight [29]. The protein
concentration of the nuclear extract was determined by the
Bradford assay [30].
Gel mobility-shift assay
Radiolabeled double-stranded synthetic oligonucleotides were
incubated with 4 .tg of nuclear extract, plus 1.5 g of poly (dI-dC),
in a final volume of 10 il containing: 10 mi Tris-HC1 (pH 7.5), 50
mM NaCl, 0.5 mivi DTT, 10% glycerol and 0.05% nonidet P-40.
The binding was allowed to proceed at room temperature for 20
minutes. The samples were subjected to low ionic strength,
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is five times more sensitive than a regular ABC kit due to the
formation of ideal complexes for immunoperoxidase staining.
SMA was not present in the glomeruli, but was strongly
immunopositive in the smooth muscle cells of blood vessels of new
born mice. The protein was also significantly immunopositive in
the mesangial cells of all of the glomeruli as well as the vessels of
one-week-old mice. This expression of SMA immunoreactivity
appeared to be constant until the mice reached eight weeks of age
(Fig. 2). These results indicated that SMA, a specific marker for
smooth muscle cells, was expressed in normal adult mouse
mesangial cells in vivo.
Identification of mesangial cells in vitro
Fig. 1. In situ hybridization for SMA mRNA in the normal adult mouse
kidney. A. Antisense probe. There were reaction products (brown) in most
of the mesangial areas of the glomerli (X350). B. Antisense probe. The
smooth muscle cells were strongly positive in the blood vessels (x700). C.
Sense probe. There were virtually no positive cells present (X350).
non-denaturing 5% polyacrylamide gel clectrophoresis, and then
analyzed by autoradiography [31].
Statistical analysis
The data were expressed as means SE, and were analyzed with
Pearson's correlation coefficient.
Results
Expression of SMA mRNA and protein in vivo
The expression of SMA within the mouse kidneys in vivo was
investigated by in situ hybridization with a specific mouse RNA
probe. The majority of the cells in the glomerular mesangium
contained SMA mRNA, whereas the epithelial and endothelial
cells were negative (Fig. 1A). The mRNA was also detected in
smooth muscle cells in the arteries and arterioles (Fig. 1B). No
SMA mRNA positive cells were found in the tubules or in the
interstitial regions (Fig. IC). Similarly, no positive reactions were
obtained when the sense probe was used. SMA protein expression
was investigated by a modified, sensitive immunoperoxidase
method. We used the metal enhanced DAB kit, which is fifty
times more sensitive than the regular DAB kit without enhance-
ment. Moreover, we also used a Vectastain Elite ABC kit, which
We examined five different mesangial cell populations. All of
these cells had been isolated by patch cloning, where groups of
less than 50 to 100 cells which resembled mesangial cells had been
isolated by a cloning ring. These cells were then passaged to
develop a cell line (Table 1). Phase microscopic examination
revealed that all of the cell populations had a stellate appearance
before reaching confluence, and then formed multiple layers of
elongated cells growing in parallel arrays after confluence. Actin
filaments, which were detected by rhodamine-phalloidin staining,
were distributed in large transcellular arrays of fibrils oriented
along the long axis of the cells (Fig. 3). Neither cytokeratin
filaments (a marker of epithelial cells) nor von Willebrand factor
VIII related antigen (a marker of endothelial cells) were detected.
None of the cell lines endocytosed acetylated low density lipopro-
tein, (a marker for endothelial cells and macrophages). Thus, all
of the mesangial cell populations fulfilled the criteria generally
accepted for glomerular smooth muscle mesangial cells previously
described [3]. Two cell populations (30 and SlO) were derived
from normal adult mice. The first population was further propa-
gated for multiple passages in order to examine the consequences
of passaging on phenotype (E < passage 25, L> 45). The NOD
cells were derived from nonobese diabetic mice (Ni and N2), a
strain which develops autoimmune diabetes mellitus and shows
early glomerulosclerotic lesions [32]. These populations were truly
clonal, since they developed from single cells. The same parent
mouse strain also gave rise to the 30 and SlO cells.
During the late passages the 30 mesangial cells (30L) grew
more rapidly than the 30E cells, with a doubling time of 18.6 hours
in 2% fetal bovine serum-medium, as compared to 25.1 hour.
However, these cells did not change morphologically. The dou-
bling time of SlO cells was 17.9 hours (Table 1).
Expression of SMA mRNAs and al (IVY) and a2(I, collagens in
mesangial cells
SMA mRNA levels were examined by Northern blot analysis
and by solution hybridization RNase protection assay. Similar
results were obtained with both methods. The protected major
band was 60 bps, which is identical to the expected band. The 3'
region of the SMA eDNA was used as a probe. Since there are
three poly A regions in this sequence, correspondingly smaller
amounts of the protected bands were detected (Fig. 4A). The
levels of SMA mRNA differed markedly in the cell lines studied.
The mRNA levels were highest in the 30E cells and lowest in the
30L, Ni, and N2 cells. The S10 cells had mRNA levels interme-
diate between the 30E cells and the others.
( 9, I,
Fig. 3. Disidhutitni of F—acii,, fl/a
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i . . I muno eroxidase staining for SMA i ormal kidneys. A. wb mou  (X 0), B. Seven- -old mo  (X350).
i . 3. Distributio  of F-actin filaments in the
mesangial ell .  staining was
performed on cel  w th rhodam ne- phalloidin
(x320). The cell lines studied were as follows:
A. 30E; 0L; C. Sb; . i; . N2 cells
The expression of genes coding for the different types of
collagens has been shown to vary between cell types. Type I
collagen is the main collagen species produced by fibroblasts in
vitro, and smooth muscle cells produce type IV collagen in
addition to type I collagen. The levels of csl(IV) collagen and
a2(I) collagen mRNAs were measured by solution hybridization
RNase protection assay. The al(IV) mRNA levels were highest in
the 30E cells, and low in the 30L, Ni and N2 cells (Fig. 4B). The
30E 30L SiC Ni N2
a -60
— S —e a —330
-210
-230
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doubling time and the levels of SMA mRNA was examined to
address the question of phenotypic modulation in the various
mesangial cell isolates. The SMA mRNA levels and the doubling
time were significantly correlated (r = 0.899, P < 0.05).
A SM cx-Actin
B c,1(IV)
C cx2(I)
Secretion of SMA and type IV and I collagen proteins
The levels of actin and collagen protein were then assessed in
the culture media. SMA, a 47 kDa protein on SDS polyacrylamide
gel electrophoresis, was examined by Western blot analysis with a
mouse monoclonal antibody specific for SMA. The levels were
highest in the 30E cells, and low in the 30L, Ni and N2 cells (Fig.
5 A, B). Therefore, the protein expression pattern was closely
related to the mRNA expression (r = 0.942, P < 0.005). Addi-
tional non-specific bands with apparent sizes of 75 kDa and 120
kDa were also detected in all of the cells, and were detected in
control experiments without primary antibody.
The amount and ratio of type IV and I collagens released into
the medium was determined by a competitive enzyme-linked
immunoassay. As expected, there was a significant correlation
between the protein and mRNA levels of type IV collagen (r =
0.973, P < 0.001; Fig. SC). Type I collagen, present in large
amounts in supernatants from Ni, N2 and SlO cells, also corre-
lated with the a2(I) mRNA levels (r = 0.899, P < 0.01; Fig. 5D).
Methylation state and regulation of transcription
D GAPDH
Fig. 4. Expression of SMA, collagens a] (IV) and a2(I), and GAPDH
mRNAs in the mesangial cell lines. Total RNA was extracted from
semicomfiuent cells on dishes coated with fibronectin, and was analyzed by
solution hybridization RNase protection assays. A. SMA mRNA; B.
al(IV) collagen mRNA; C. a2(I) collagen mRNA; D. GAPDH mRNA.
Densitometric analysis was also performed on the smooth muscle actin (N
= 4) (E), al(IV) collagen (N = 4) (F), and a2(I) collagen (N = 4) (F).
The densitometoric data were as follows. The levels of SMA mRNA were:
2.12, 0.07, 0.83, 0.11, and 0.27; the levels of al(IV)collagen were: 1.16,
0.16, 0.53, 0.20, and 0.31 in the 30E, 30L, Sb, Ni, N2 cells, respectively.
The level of SMA mRNA correlated significantly with the doubling time
(Pearson's correlation coefficient; r 0.89946, T = 3.564, P = 0.0376).
levels of al(IV) mRNA paralleled the pattern of SMA expression
(r = 0.998, P < 0.001). The converse was true for a2(I) mRNA,
which was the highest in the Ni, N2 and SlO cells and essentially
undetectable in the 30E cells (Fig. 4C). Thus, there was a
correlation between the levels of SMA and al(IV) mRNAs, and
an inverse tendency between these two and the levels of a2(I)
mRNA in the 30E, Sb, Ni, N2 cells (Fig. 4 A-C). Mouse
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as
the control gene (Fig. 4D).
The expression of a2 type I collagen was proportional to the
doubling time; it was the lowest in the cells with high levels of
SMA mRNA, but increased in cells with a shortened doubling
time and lower levels of SMA. The relationship between the
The role of DNA methylation in the transcriptional regulation
elements of these genes was examined with the methyl-sensitive
restriction enzyme HpaII, which will not cleave CCGG sites, and
its isoschizome MspI, which will cut CCGG sites if the internal
cytosine is methylated. Neither enzyme will cut if the external
cytosine is methylated [331.
The CCGG sites in the SMA promoter elements were analyzed
in DNA samples digested with HindIII+MspI or HindIII+HpaII.
MSPI and HpaII digests of the 30E and SlO cells, in which the
mRNA was abundantly expressed, contained a prominent 2.4 kbp
band, thus indicating that the gene was unmethylated. There was
a larger molecular band in the HpaII digest from 30L, Ni and N2
cells. This band indicated that the cis-elements of this gene were
methylated (Fig. 6A), which was agreement with its low level of
mRNA expression (Fig. 4A).
The methylation patterns of the type IV collagen promoter and
its enhancer elements were analyzed using MspI and HpaII [34].
The gene was unmethylated in 30E cells, which was in agreement
with its high level of mRNA expression. However, this region was
methylated in 30L, Sb, Ni and N2 cells, and there was a
correspondingly lower level of expression. The MspI digests
showed a 2.3 kbp band as well as a 1.8 kbp band in these cells,
indicating that the external cytosine was methylated (Fig. 6B).
The methylation patterns of the promoter/enhancer elements
of the a2(I) collagen gene also correlated with the levels of
mRNA expression (Figs. 4C and 6C). As judged by the presence
of 0.4 kbp and 3.5 kbp bands, the gene must have been methylated
in 30E cells, where its mRNA was not expressed. The gene was
partially methylated in 30L cells, but unmethylated in Sb, Ni and
N2 cells.
Trans-acting elements
The role of the trans-acting elements in the regulation of
transcription was investigated by transiently transfecting with
A 3OE3OLS1ON1 N2
lO6kD-
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Fig. 5. Analysis of protein products in the
mesangial cell lines. A. Western blot analysis for
SMA. Proteins were extracted from the cells
with 8 M urea buffer and analyzed with a
monoclonal antibody for SMA. The 45 kDa
band was specific for SMA. B. Densitimetric
analysis of the immunoreactive band for SMA
(N = 2). C. Collagen type IV secretion into the
media (N 2). D Collagen type I secretionN2 into the media (N = 2).
Fig. 6. Methylation patterns of the regulatoiy elements in the mesangial cell lines. A. Promoter elements of SMA. M: MspI+HindIII, H: HpaII+Hindffl.
B. Promoter/enhancer elements of al(IV) collagen. M: MspI, H: HpaIJ. C. Promoter/enhancer elements of a2(I) collagen. M: MspI, H: HpaII.
fusion constructs that contained the promoter/enhancer/chloram- with pSV-p-galactosidase as the internal control. pSVOCAT and
phenicol acetyltransferase (CAT) for each gene. A correction for pSV2CAT were used as negative (0%) and positive (100%)
the transfection efficiency was accomplished by cotransfection controls, respectively [25]. The experiments were performed on
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30E, Ni and N2 cells. We were unable to efficiently introduce the
construct into 30L and SlO cells by the calcium-phosphate
method.
The activity of the trans-acting transcription factors which were
bound to the SMA promoter was analyzed by using SMP-l, which
contained the SMA promoter, the SV40 T antigen enhancer and
the CAT reporter gene. SMP-l promoted CAT activity in 30E, Ni
and N2 cells (Fig. 7A). However, there was no correlation
between the absolute levels of CAT activity and the levels of SMA
mRNA expression; in other words, the trans-acting factors in N2
cells were activated. These data indicated that the endogenous,
methylated SMA promoter regulated mRNA expression.
Transient transfection with p56, which contained the promoter!
enhancer elements of the type IV collagen and CAT genes,
showed 5.6 to 10.3% of the corrected CAT activity (Fig. 7B). As
with SMA, there was no correlation between the transcriptional
activity and the level of mRNA expression. These data also
suggested that the methylation state of the endogenous gene
influenced mRNA expression.
Following transfection with pR40, which contained the promot-
er!enhancer from a2(I) and the CAT gene, low levels of CAT
activity were detected in the 30E cells and high levels were
detected in the Ni and N2 cells (Fig. 7C). Therefore, the
transcriptional activity of pR4O correlated with the level of mRNA
expression. These data suggest that the transcription of SMA and
al(IV) collagen genes was regulated by the methylation state of
the enhancer and!or promoter elements. The data also suggest
that the transcription of the a2(I) collagen gene was regulated by
both cis-regulators and trans-acting elements.
Modulation of DNA methylation by 5-azacytidine
The role of methylation in modifying gene expression was
evaluated in early (30E) and late (30L) passage cells treated with
5-azacytidine, an agent which blocks DNA methylation in dividing
cells. Treatment of the 30L cells for four days with 5-azacytidine
resulted in elevated levels of both SMA and al(IV) mRNAs (Fig.
8A). Although the promoter!enhancer elements of c2(I) were
partially methylated in the 30L cells, a2(I) mRNA decreased after
treatment with 5-azacytidine. The levels of mouse glyceraldehyde-
3-phosphate dehydrogenase mRNA remained constant (Fig. 8A).
SMA and cil(IV) genes are unmethylated in the 30E cells, and in
these cells 5-azacytidine did not increase the mRNA level (Fig.
8B). Interestingly, although a2(I) was methylated in the 30E cells,
5-azacytidine did not induce the expression of this gene. These
data suggest that both SMA and cwl(IV) genes were regulated by
structural modifications of the cis-regulators, whereas the a2(I)
gene was mainly regulated by its trans-acting elements.
The possibility that 5-azacytidine treatment might modify these
trans-acting elements was examined by transfecting 30L cells with
pR4O (ci2(I)!CAT gene) by a modified calcium-phosphate
method, using 100 jig/mI chloroquine during the transfection and
glycerol shock afterwards to increase the efficiency. Treatment
with 5-azacytidine resulted in significantly decreased CAT activity
(Fig. 9). Thus, the activity of the trans-acting factors which
controlled the expression of the a2(I) gene was regulated by
treatment with 5-azacytidine in the 30L cells.
Regulation of transcription factors
Transcriptional regulatory proteins that bound to the promoter
or enhancer of the a2(I) collagen gene were identified by gel
mobility-shift assay. Figure IOA reveals the gel mobility shift of a
31 bp fragment from the promoter region when incubated with
nuclear extracts prepared from the 30E, 30L or 30L cells treated
with 5-azacytidine. The assay used excess amounts of the labeled
probe, a non-specific competitor (poly (dI-dC)) and nuclear
extracts. The specificity of the gel mobility-shift assay was sup-
ported by the fact that the signal could be competed out by excess
amounts of the unlabeled target DNA, but not by an unrelated
DNA. The intensity of the shifted band also correlated with the
amount of nuclear extract on the assay. There was a correlation
between the intensity of the migrated band and the levels of a2(I)
collagen mRNA expression. A 20 bp fragment from the enhancer
was end-labeled and incubated with nuclear extracts prepared
from the 30E, 30L or 30L cells treated with 5-azacytidine. Figure
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Fig. 7. Analysis of transcription activity with a transient transfection assay.
The promoter activity of SMA (A), the promoter/enhancer activity of
al(IV) collagen (B) and the promoter/enhancer activity of a2(I) collagen(C) were analyzed in the mesangial cell lines (30E, Ni and N2).
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Fig. 8. Effects of 5-azacytidine on the expression of mRNA in 30L (A) and 30E cells (B). After the cells were treated with iO- M of 5-azacytidine for four
days, the specific RNAs were determined by solution hybridization RNase protection assay. Abbreviations are: C, control; A, 5-azacytidine treatment.
lOB demonstrates the unique shift pattern found in the 30E cells
as compared with the 30L or 30L cells treated with 5-azacytidine.
This suggests that the state of the trans-acting factors changed
during many passages.
Discussion
SMA, whose expression is limited to smooth muscle cells in the
adult animal, has often been used as a marker for smooth muscle
differentiation, both in vivo and in vitro [35—38]. We found by in
situ hybridization that SMA was expressed in mesangial cells from
the normal kidneys of adult mice. SMA protein was also found in
the mesangial cells from the normal kidneys of one-week-old to
adult mice. However, no glomeruli from new born mice were
immunopositive. Thus, in normal adult mouse kidneys, the mes-
angial cells had phenotypic characteristics of smooth muscle cells,
which had been differentiated from newborn mice.
It has been assumed that the spindle-shaped, contractile cells in
outgrowths from isolated glomeruli were smooth muscle cells
derived from the glomerular mesangium [3]. However, analysis of
the ECM proteins synthesized by these cells has raised questions
about this conclusion, and specific markers have not been avail-
able until now [3, 39, 40]. We found that, although all of the cell
lines were morphologically similar and fulfilled many of the
criteria accepted for their designation as mesangial cells, they had
widely varying levels of SMA mRNA. Nonetheless, the presence
of SMA mRNA coupled with the other characteristics of these
cells allowed for most of these cell lines to be categorized as
mesangial smooth muscle cells. Finally, while not often com-
mented upon, mesangial cells which are capable of being propa-
gated in vitro had shortened doubling times, in sharp contrast to
the physiologic cell turn over in vivo in mice and rats [3, 41].
The levels of SMA mRNA paralleled those of al(IV) collagen,
both of which are features of smooth muscle cells. The levels of
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Fig. 9. Effects of 5-azcytidine on the promoter/enhancer activity of the a2(I)
collagen gene in 30L cells. The cells were treated with 5-azacytidine, and
then examined for the CAT activity of the fusion gene, consisting of the
promoter/enhancer of a2(I) collagen and a CAT reporter gene. Abbrevi-
ations are: C, control; A, 5-azacytidine treatment.
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Fig. 10. Gel-shift mobility assay. A. The gel mobility shift assay used double-stranded 32P-labeled 31-bps oligonucleotides derived from the promoter of
a2(l) collagen. These oligonucleotides were then incubated with nuclear extracts (lanes 2 to 9). Lane 1, no nuclear extract. The nuclear extracts were
isolated from 30E (lane 7), 30L (lanes 2 to 6, 8) and 5-azacytidine treated 30L cells (lane 9). The amount of nuclear extract added in each lane is as
follows. Lane 2,3 and 6 to 9; 4 jig, Lane 4; 8 .tg, Lane 5; 12 sg, respectively. Unlabeled oligonucleotides were added to the DNA-binding reaction as
competitors (lanes 2, 6). Lane 2, unlabeled 31-bps oligonucleotides. Lane 6, unrelated oligonucleotides containing Oct-i binding sequence. The
competitor oligonucleotides were present in a 200-fold molar excess over the labeled probe. B. The gel mobility shift of a 20-bps fragment from the
enhancer of the u2(I) collagen gene. Lane 1, no nuclear extrence. The competitor oligonucleotides were present in a 200-fold molar excess over the
labeled probe. C. The gel mobility shift of a 20-bps fragment from the enhancer of the a2(I) collagen gene. Lane 1, no nuclear extract. The nuclear
extracts were isolated from 30E (lanes 2, 3), 30L (lanes 4, 5) and 5-azacytidine treated 30L cells (lanes 6 to 11). The amount of nuclear extract added
in each lane is as follows. Lanes 2 to 7; 4 .rg, Lane 8; 2 .rg, Lane 9 and 11; 5 .sg, Lane 10; 12.5 rg, respectively. Unlabeled oligonucleotides were added
to the DNA-binding reaction as competitors (lanes 3, 5, 7 and 11). Lanes 3, 5, 7, unlabeled 20-bps oligonucleotides. Lane 11, unrelated oligonucleotides
containing Oct-i binding sequence. The amount of competitors is same as A.
SMA and al(IV) collagen mRNAs were inversely correlated with
the doubling time, and were in concert with other phenotypic
changes. The protein levels also paralleled the mRNA levels for
each of the genes examined. These findings indicated that SMA
expression in cultured mesangial cells may provide a useful tool to
explore the mechanisms by which phenotypic modulation occurs
in vivo and in vitro. Furthermore, these data suggested that there
was considerable variation in the smooth muscle phenotype
between the various mesangial cell populations. One population
which was studied serially revealed a shift towards a phenotype
which has been found to be prototypical of mesangial cells in vitro.
This change in phenotype has been termed dedifferentiation [42];
however, the sequence of events in the dedifferentiation of
mesangial cells has not been elucidated in vivo.
Others have predicted the existence of switch genes, which
would be responsible for activating a battery of genes for one
developmental pathway. The myo D and myogenin genes have
been described to play such a role in striated muscle [43, 44]. The
factors involved in the determination of smooth muscle lineage,
the commitment to terminal differentiation and/or the mainte-
nance of the smooth muscle phenotype still remain unknown. This
study indicated that SMA was a useful marker of the smooth
muscle mesangial cell phenotype, but its expression in vitro was
not limited to mesangial cell populations, which closely mimics the
in vivo situation. These in vitro mesangial cells showed the
different stages of differentiation, which may become important
tools for exploring the switch mechanism of phenotypic change.
During normal differentiation in vivo, SMA was only expressed in
differentiated mesangial cells and smooth muscle cells in the
vessel wall.
Although the events controlling gene activation and inactiva-
tion have not been completely elucidated, the cytosine residues in
the promoter or enhancer elements have often been found to be
unmethylated in actively expressed genes [45, 46]. DNA methyl-
ation was also found to prevent the binding of specific transcrip-
tion factors to the DNA [47]. Trans-regulatory proteins have also
been shown to play a role in activating specific genes. In addition,
numerous DNase-sensitive sites have been found in actively
expressed genes, thus indicating that they are accessible to
extrachromosomal molecules such as transcription factors [48].
We analyzed the methylation state of the enhancer and/or pro-
moter elements, and the activity of trans-acting DNA binding
proteins. The levels of the SMA and csl(IV) collagen genes both
correlated with the degree of methylation. On the other hand, the
expression of the a2(I) collagen gene appeared to be regulated by
the trans-acting elements, as well as by the methylation state. In
summary, the expression of mesangial cell genes for SMA, al(IV)
and cs2(I) collagen are regulated by different transcriptional
means in vitro.
After the treatment of 30L cells with 5-azacytidine, there was an
increase in the levels of both SMA and al(IV) collagen mRNAs.
Since the levels of a2(I) collagen mRNA decreased, its transcrip-
tion was also assumed to have been decreased by the 5-azacytidine
treatment. To elucidate the effects of 5-azacytidine treatment on
cs2(I)collagen transcription, we performed a gel mobility-shift
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assay using the promoter or enhancer elements of the a2(I)col-
lagen gene. In the case of the promoter elements, the trans-acting
factors would be increased in the late passage cells, and thus
5-azacytidine treatment would down-regulate these transacting
factors to the levels of earlier passage cells. On the other hand, in
the case of the enhancer elements, 5-azacytidine treatment would
induce other trans-acting factors, These results suggest that a
promoter binding protein would be a positive transcription factor,
and would play a significant role in the transcription of the
a2(l)collagen gene. It is still unclear whether the enhancer
binding factors induced by 5-azacytidine are actually suppressive
factors. These data are consistent with previous studies reporting
that both SMA and al (IV) collagen genes were regulated by both
cis-acting elements and trans-acting elements [34, 49]. The data
also suggested that mechanisms other than, or in addition to,
cytosine methylation were important in a2(I) collagen gene
activation [231.
One reason that we were able to successfully isolate a mesangial
cell population with a mature phenotype may have been related to
the relatively slow outgrowth of cells from mouse glomeruli under
our culture conditions. Several months were required to establish
homogenous populations, in contrast to most rat and human cells
which were established in a few weeks [3]. The phenotype of the
population, which initially had a collagen biosynthetic pattern
which resembled the in vivo pattern, gradually shifted as the
number of passages increased. In addition, the growth rate also
gradually increased. Rat and human mesangial cells in vitro have
been shown to synthesize principally interstitial matrix compo-
nents rather than basement membrane components [4]. This
biosynthetic pattern has been shown to be characteristic of a
fibroblast phenotype in vitro. One possible explanation for this
inconsistency in the in vitro phenotype from the in vivo phenotype
may have been the fact that the tissue culture conditions selected
for rapidly growing cells. Furthermore, this rapid multiplication
rate was associated with an abnormal collagen phenotype.
There are two main mechanisms by which the observed change
in the phenotype of mesangial cell populations could have oc-
curred after multiple passages in vitro. The first possibility is that
a minor subpopulation of more rapidly growing cells gradually
became the predominant cell type. The second is a doeumentable
change in the phenotype of a major cell type in the primary
isolate. Two observations suggest that the observed change in
phenotype was due to on actual change in the phenotype rather
than on overgrowth of a minor population. First, the cell lines
were initially derived by cloning from small patches of no more
than 50 cells. The observed changes in phenotype also did not
appear until after the cells had been passaged over 25 times, which
represents more than 60 doublings. If the change was due to an
overgrowth of a different population that was present in the initial
isolate as a small contaminant, the phenotypie change would have
been expected to appear at a much earlier passage number. The
second reason was the observation that the newly appearing
phenotype could be reversed, in part, by changing the methylation
state of the CCGG motifs. The more rapid turnover rate hi the
late passage cells and the change in collagen phenotype were
consistent with our findings in glomeruloselerotic lesions from
mice transgenic for growth hormone [50].
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